Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.
Mühlbacher J, Schörgenhofer C, Doberer K, Dürr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Böhmig GA. Mühlbacher J, et al. Among authors: mayer ka. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8. Transpl Int. 2021. PMID: 34153143 Free PMC article. Clinical Trial.
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, Agis H, Reiter T, Reindl-Schwaighofer R, Wahrmann M, Cohen G, Haslacher H, Bond G, Simonitsch-Klupp I, Halloran PF, Böhmig GA. Doberer K, et al. Among authors: mayer ka. Transplantation. 2021 Feb 1;105(2):451-457. doi: 10.1097/TP.0000000000003247. Transplantation. 2021. PMID: 32235256
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA. Mayer KA, et al. Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9. Trials. 2022. PMID: 35395951 Free PMC article.
Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pretransplant Biopsies: A Prospective Observational Study.
Haupenthal F, Kläger J, Bauernfeind F, Heinzel A, Doberer K, Mayer K, Naar L, Eigenschink M, Hu K, Regele H, Szekeres T, Berlakovich G, Reindl-Schwaighofer R, Bond G. Haupenthal F, et al. Transplantation. 2022 Oct 1;106(10):2044-2051. doi: 10.1097/TP.0000000000004134. Epub 2022 Apr 11. Transplantation. 2022. PMID: 35504006
Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection.
Borski A, Kainz A, Kozakowski N, Regele H, Kläger J, Strassl R, Fischer G, Faé I, Wenda S, Kikić Ž, Bond G, Reindl-Schwaighofer R, Mayer KA, Eder M, Wahrmann M, Haindl S, Doberer K, Böhmig GA, Eskandary F. Borski A, et al. Among authors: mayer ka. Front Med (Lausanne). 2022 Apr 21;9:817127. doi: 10.3389/fmed.2022.817127. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35530045 Free PMC article.
42 results